Novel monoclonal antibodies against thymidine kinase 1 and their potential use for the immunotargeting of lung, breast and colon cancer cells
Open Access
- 16 April 2020
- journal article
- research article
- Published by Springer Nature in Cancer Cell International
- Vol. 20 (1) , 1-20
Abstract
Background: Thymidine kinase 1 (TK1) is a pyrimidine salvage pathway enzyme that is up-regulated in malignant tissues and elevated in the serum of cancer patients. While TK1 has been well established as a tumor biomarker, little has been done to explore its potential as a tumor target. Recently, we reported the membrane expression of TK1 on malignant cells, but not on normal cells. This study explores the possible use of monoclonal antibodies for the targeting of membrane associated TK1 in lung, breast, colon and prostate cancer cells. Methods: We generated and evaluated a panel of monoclonal antibodies against six different epitopes exposed in the tetrameric form of TK1. Antibodies were developed with hybridoma technology and validated with Western blot, siRNA TK1 knockdown, enzyme-linked immunosorbent assay (ELISA) and flow cytometry. The therapeutic potential of the antibodies was evaluated in vitro in antibody-dependent cell-mediated-cytotoxicity (ADCC) experiments. Results: Binding of the antibodies to TK1 was confirmed by Western blot in purified recombinant protein, cancer serum, and cell lysate. After a TK1 knockdown was performed, a reduction of TK1 expression was observed with five antibodies. Using indirect ELISA, we identified 3B2E11, 9C10, 7H2, 3B4, 8G2 among the most sensitive antibodies (LOD = 10.73–66.9 pg/ml). Surface expression of TK1 on the membrane of various cancer cell lines was analyzed with flow cytometry. Antibodies 8G2, 3B4, 7HD and 5F7G11 detected TK1 on the membrane of various cancer cell lines, including lung, prostate, colon and breast. No significant binding was detected on normal lymphocytes. Increased cytolysis of lung (~ 70%. p = 0.0001), breast (~ 70%, p = 0.0461) and colon (~ 50% p = 0.0216) cancer cells by effector cells was observed when anti-TK1 antibodies were added during ADCC experiments. Conclusions: The antibodies developed showed potential to be used to detect and target TK1 on the membrane of various tumor cells. The targeting of TK1 in malignant cells using monoclonal antibodies may be a feasible approach for the elimination of high TK1 expressing tumor cells.Keywords
This publication has 48 references indexed in Scilit:
- Understanding key assay parameters that affect measurements of trastuzumab-mediated ADCC against Her2 positive breast cancer cellsOncoImmunology, 2012
- Quaternary structures of recombinant, cellular, and serum forms of Thymidine Kinase 1 from dogs and humansBMC Biochemistry, 2012
- Thymidine Kinase 1 Upregulation Is an Early Event in Breast Tumor FormationJournal of Oncology, 2012
- Serological Thymidine Kinase 1 is a Biomarker for Early Detection of Tumours—A Health Screening Study on 35,365 People, Using a Sensitive Chemiluminescent Dot Blot AssaySensors, 2011
- Exposed proliferation antigen 210 (XPA‐210) in renal cell carcinoma (RCC) and oncocytoma: clinical utility and biological implicationsBJU International, 2011
- Thymidine Kinase 1 is a Potential Marker for Prognosis and Monitoring the Response to Treatment of Patients with Breast, Lung, and Esophageal Cancer and Non-Hodgkin's LymphomaNucleosides, Nucleotides & Nucleic Acids, 2010
- Serum thymidine kinase 1 correlates to clinical stages and clinical reactions and monitors the outcome of therapy of 1,247 cancer patients in routine clinical settingsInternational Journal of Clinical Oncology, 2010
- International Lung Cancer Consortium: Coordinated association study of 10 potential lung cancer susceptibility variantsCarcinogenesis, 2010
- Thymidine kinase 1 – A prognostic and diagnostic indicator in ALL and AML patientsLeukemia, 2007
- Thymidine kinase: a tumor marker with prognostic value for non-Hodgkin's lymphoma and a broad range of potential clinical applicationsAnnals of Hematology, 1992